[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @DrChoueiri Toni Choueiri, MD Toni Choueiri, MD posts on X about breast cancer, trend in, nac, combo the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::4827883464/interactions)  - X Month XXXXXX +206% - X Months XXXXXXX -XX% - X Year XXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::4827883464/posts_active)  - X Month XX +267% - X Months XX +9.10% - X Year XXX +104% ### Followers: XXXXXX [#](/creator/twitter::4827883464/followers)  - X Month XXXXXX +0.82% - X Months XXXXXX +4.90% - X Year XXXXXX +11% ### CreatorRank: XXXXXXX [#](/creator/twitter::4827883464/influencer_rank)  ### Social Influence [#](/creator/twitter::4827883464/influence) --- **Social category influence** [countries](/list/countries) **Social topic influence** [breast cancer](/topic/breast-cancer) #211, [trend in](/topic/trend-in), [nac](/topic/nac), [combo](/topic/combo), [rc](/topic/rc), [ct](/topic/ct), [os](/topic/os) #969, [italy](/topic/italy), [germany](/topic/germany), [rna](/topic/rna) ### Top Social Posts [#](/creator/twitter::4827883464/posts) --- Top posts by engagements in the last XX hours "Practice-shaping presidential caliber from @Prof_Nadia_H DESTINY-Breast11: neoadjuvant T-DXdTHP tops ddAC-THP on pCR XXXX% vs XXXX% (11.2% p=0.003). Early positive trend in EFS. #ESMO25 #BreastCancer @myESMO @Annals_Oncology @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979559687948509229) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T14:46Z 42.9K followers, 2876 engagements "Patient-reported outcomes hold up in NIAGARA trial by @MichvdHeijden: periop durvalumab+NAC (Arm D) vs NAC alone (Arm C). No HRQoL detriment; TTDD trends longer with Arm D; GHS/QoL HR XXXX pain HR XXXX. EFS/OS gains without QoL cost. #ESMO25 @myESMO @Annals_Oncology @OncoAlert @OncLive @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979187138139697558) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T14:05Z 42.9K followers, 1646 engagements "FGFR3 precision push by #AlexandraDrakaki in FORAGER-1 Ph.I: LY3866288 hits IC90 at XXX mg BID; ORR XX% at XXX mg (n=28) and XX% XXX mg (n=82). Combo with EV+pembro opening. #ESMO25 @myESMO @Annals_Oncology @OncLive @OncoAlert @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979189298571170036) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T14:14Z 42.9K followers, 3315 engagements "Kidney-sparing challenge to RNU in DISTINC-I trial Ph.II presented by #JiweiHuang : DV+tislelizumab + endoscopic/segmental surgery: cCR XXXX% (3 mo) 1-y kidney-intact EFS 68.4%; no G3 systemic tox. Biomarker: HER2 overexpression 3+/2+ in 42%. #ESMO25 @myESMO @Annals_Oncology @OncoAlert @OncLive @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979201788302516649) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T15:04Z 42.9K followers, 1631 engagements "@katy_beckermann insightful presentation showing adenosine A2a Rc Antag add-on that falls short in a Ph. Ib/II trial: Ipi/nivo+ciforadenant: ORR XX% mPFS XXX mo. No efficacy lift over IO benchmarks. #ESMO25 #RCC @myESMO @ASCOpost @OncoAlert @OncLive @Annals_Oncology" [X Link](https://x.com/DrChoueiri/status/1979206218389352536) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T15:21Z 42.9K followers, XXX engagements "Novel and exciting data by @BernatzSimon AI-graded thymic health from baseline CT predicts IO outcomes pan-cancer. high vs low PFS HR 0.59; OS HR XXXX after adjustment. Signal consistent across PD-L1/TMB strata. Future host-specific IO-marker #ESMO25 #AI @myESMO @DanaFarber @harvardmed" [X Link](https://x.com/DrChoueiri/status/1979475533327966399) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T09:11Z 42.9K followers, XXX engagements "We have Italy Germany and the UK @myESMO #ESMO25 Presidential I. Come on down" [X Link](https://x.com/DrChoueiri/status/1979554762354819157) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T14:26Z 42.9K followers, XXX engagements "4th and final Practice-relevant win presidential for today by #NicolettaColombo. ENGOT-ov65/KEYNOTE-B96: pembro + weekly paclitaxel +/- bev improves PFS (8.3 vs XXX mo; HR 0.70) in platinum-resistant ovarian cancer and OS benefit in PD-L1 CPS1 (HR 0.76). #ESMO25 #OvarianCancer @myESMO @OncLive @Annals_Oncology @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979580404978827266) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T16:08Z 42.9K followers, 2552 engagements "Influential high-impact biomarker presentation by @DrRanaMcKay with LAG3 expression: LAG3-high tumors show inflamed RNA expression (PD-L1/CTLA4/TIGIT) and better early IO response; low LAG3 reduced real-world ORR & more PD across 1L IO. #ESMO25 #RCC @myESMO @Annals_Oncology @OncLive @OncoAlert @OncBrothers" [X Link](https://x.com/DrChoueiri/status/1979799086787096751) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-19T06:37Z 42.9K followers, 1196 engagements "A state-of-the-art session by @tompowles1 he truly put his heart into it. From EV+pembro transforming urothelial cancer to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L TNBC NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO @Annals_Oncology @OncoAlert @OncBrothers @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979499036194246977) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T10:45Z 42.9K followers, XXX engagements "Head-to-head win presented by #ShunLu: ivonescimab+chemo beats tislelizumab+chemo in 1L squamous NSCLC: PFS XXXX vs XXX mo (HR XXXX p0.0001). Practice-informing; OS pending. #ESMO25 #NSCLC @myESMO @Annals_Oncology @OncoAlert @OncLive" [X Link](https://x.com/DrChoueiri/status/1979920993406615680) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-19T14:42Z 42.9K followers, 1285 engagements "ADC + PD-1/TIGIT signal by #SunYoungRha in TROPION-PanTumor03 Ph.II study: Dato-DXd+rilve in a/mUC: ORR XX% 1L XX% 2L; PFS NR (1L) XXXX mo (2L). G3 TRAEs XX% (1L)/39% (2L). Encouraging controllable toxicity. #ESMO25 @myESMO @ASCOpost @OncoAlert @OncLive @DanaFarber @Annals_Oncology" [X Link](https://x.com/DrChoueiri/status/1979190848085446850) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T14:20Z 42.9K followers, 1455 engagements "Promising adjuvant RCC moment by #JamesLarkin discussing RAMPART Ph.III trial: durvalumab +/- tremelimumab after nephrectomy. DFS HR XXXX (95% CI 0.45-0.93); p=0.009. Significant DFS HR XXXX in the high risk grp. #ESMO25 #RCC @myESMO @OncoAlert @OncLive @Annals_Oncology" [X Link](https://x.com/DrChoueiri/status/1979450311866749011) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T07:31Z 42.9K followers, 1138 engagements "A state-of-the-art session by @tompowles1 he truly put his heart into it. From EV+pembro transforming urothelial cancer to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO @Annals_Oncology @OncoAlert @OncBrothers @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979508739951509898) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T11:23Z 42.9K followers, 6661 engagements "Landmark practice-changing readout delivered by #Charlesgayer shifting SOC. DESTINY-Breast05 Ph. III shows T-DXd beating T-DM1 post-neoadjuvant in high-risk HER2+ eBC (IDFS HR XXXX XX% CI 0.34-0.66 p 0.001). #ESMO25 #BreastCancer @myESMO @OncLive @OncoAlert @DanaFarber" [X Link](https://x.com/DrChoueiri/status/1979568135159283752) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T15:19Z 42.9K followers, 2617 engagements "Practice shifting huge win by #JunGuo in HER2-expressing la/mUC: DV+toripalimab chemo: PFS XXXX vs XXX mo (HR 0.36) and OS XXXX vs XXXX mo (HR 0.54). Grade3 TRAE XX% vs 87%. #ESMO25 #BladderCancer @myESMO @Annals_Oncology @OncoAlert" [X Link](https://x.com/DrChoueiri/status/1979949205767721262) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-19T16:34Z 42.9K followers, 1554 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@DrChoueiri Toni Choueiri, MD
Toni Choueiri, MD posts on X about breast cancer, trend in, nac, combo the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Month XXXXXX +206%
- X Months XXXXXXX -XX%
- X Year XXXXXXX -XX%
Mentions: XX #
- X Month XX +267%
- X Months XX +9.10%
- X Year XXX +104%
Followers: XXXXXX #
- X Month XXXXXX +0.82%
- X Months XXXXXX +4.90%
- X Year XXXXXX +11%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence countries
Social topic influence breast cancer #211, trend in, nac, combo, rc, ct, os #969, italy, germany, rna
Top Social Posts #
Top posts by engagements in the last XX hours
"Practice-shaping presidential caliber from @Prof_Nadia_H DESTINY-Breast11: neoadjuvant T-DXdTHP tops ddAC-THP on pCR XXXX% vs XXXX% (11.2% p=0.003). Early positive trend in EFS. #ESMO25 #BreastCancer @myESMO @Annals_Oncology @DanaFarber"
X Link @DrChoueiri 2025-10-18T14:46Z 42.9K followers, 2876 engagements
"Patient-reported outcomes hold up in NIAGARA trial by @MichvdHeijden: periop durvalumab+NAC (Arm D) vs NAC alone (Arm C). No HRQoL detriment; TTDD trends longer with Arm D; GHS/QoL HR XXXX pain HR XXXX. EFS/OS gains without QoL cost. #ESMO25 @myESMO @Annals_Oncology @OncoAlert @OncLive @DanaFarber"
X Link @DrChoueiri 2025-10-17T14:05Z 42.9K followers, 1646 engagements
"FGFR3 precision push by #AlexandraDrakaki in FORAGER-1 Ph.I: LY3866288 hits IC90 at XXX mg BID; ORR XX% at XXX mg (n=28) and XX% XXX mg (n=82). Combo with EV+pembro opening. #ESMO25 @myESMO @Annals_Oncology @OncLive @OncoAlert @DanaFarber"
X Link @DrChoueiri 2025-10-17T14:14Z 42.9K followers, 3315 engagements
"Kidney-sparing challenge to RNU in DISTINC-I trial Ph.II presented by #JiweiHuang : DV+tislelizumab + endoscopic/segmental surgery: cCR XXXX% (3 mo) 1-y kidney-intact EFS 68.4%; no G3 systemic tox. Biomarker: HER2 overexpression 3+/2+ in 42%. #ESMO25 @myESMO @Annals_Oncology @OncoAlert @OncLive @DanaFarber"
X Link @DrChoueiri 2025-10-17T15:04Z 42.9K followers, 1631 engagements
"@katy_beckermann insightful presentation showing adenosine A2a Rc Antag add-on that falls short in a Ph. Ib/II trial: Ipi/nivo+ciforadenant: ORR XX% mPFS XXX mo. No efficacy lift over IO benchmarks. #ESMO25 #RCC @myESMO @ASCOpost @OncoAlert @OncLive @Annals_Oncology"
X Link @DrChoueiri 2025-10-17T15:21Z 42.9K followers, XXX engagements
"Novel and exciting data by @BernatzSimon AI-graded thymic health from baseline CT predicts IO outcomes pan-cancer. high vs low PFS HR 0.59; OS HR XXXX after adjustment. Signal consistent across PD-L1/TMB strata. Future host-specific IO-marker #ESMO25 #AI @myESMO @DanaFarber @harvardmed"
X Link @DrChoueiri 2025-10-18T09:11Z 42.9K followers, XXX engagements
"We have Italy Germany and the UK @myESMO #ESMO25 Presidential I. Come on down"
X Link @DrChoueiri 2025-10-18T14:26Z 42.9K followers, XXX engagements
"4th and final Practice-relevant win presidential for today by #NicolettaColombo. ENGOT-ov65/KEYNOTE-B96: pembro + weekly paclitaxel +/- bev improves PFS (8.3 vs XXX mo; HR 0.70) in platinum-resistant ovarian cancer and OS benefit in PD-L1 CPS1 (HR 0.76). #ESMO25 #OvarianCancer @myESMO @OncLive @Annals_Oncology @DanaFarber"
X Link @DrChoueiri 2025-10-18T16:08Z 42.9K followers, 2552 engagements
"Influential high-impact biomarker presentation by @DrRanaMcKay with LAG3 expression: LAG3-high tumors show inflamed RNA expression (PD-L1/CTLA4/TIGIT) and better early IO response; low LAG3 reduced real-world ORR & more PD across 1L IO. #ESMO25 #RCC @myESMO @Annals_Oncology @OncLive @OncoAlert @OncBrothers"
X Link @DrChoueiri 2025-10-19T06:37Z 42.9K followers, 1196 engagements
"A state-of-the-art session by @tompowles1 he truly put his heart into it. From EV+pembro transforming urothelial cancer to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L TNBC NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO @Annals_Oncology @OncoAlert @OncBrothers @DanaFarber"
X Link @DrChoueiri 2025-10-18T10:45Z 42.9K followers, XXX engagements
"Head-to-head win presented by #ShunLu: ivonescimab+chemo beats tislelizumab+chemo in 1L squamous NSCLC: PFS XXXX vs XXX mo (HR XXXX p0.0001). Practice-informing; OS pending. #ESMO25 #NSCLC @myESMO @Annals_Oncology @OncoAlert @OncLive"
X Link @DrChoueiri 2025-10-19T14:42Z 42.9K followers, 1285 engagements
"ADC + PD-1/TIGIT signal by #SunYoungRha in TROPION-PanTumor03 Ph.II study: Dato-DXd+rilve in a/mUC: ORR XX% 1L XX% 2L; PFS NR (1L) XXXX mo (2L). G3 TRAEs XX% (1L)/39% (2L). Encouraging controllable toxicity. #ESMO25 @myESMO @ASCOpost @OncoAlert @OncLive @DanaFarber @Annals_Oncology"
X Link @DrChoueiri 2025-10-17T14:20Z 42.9K followers, 1455 engagements
"Promising adjuvant RCC moment by #JamesLarkin discussing RAMPART Ph.III trial: durvalumab +/- tremelimumab after nephrectomy. DFS HR XXXX (95% CI 0.45-0.93); p=0.009. Significant DFS HR XXXX in the high risk grp. #ESMO25 #RCC @myESMO @OncoAlert @OncLive @Annals_Oncology"
X Link @DrChoueiri 2025-10-18T07:31Z 42.9K followers, 1138 engagements
"A state-of-the-art session by @tompowles1 he truly put his heart into it. From EV+pembro transforming urothelial cancer to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO @Annals_Oncology @OncoAlert @OncBrothers @DanaFarber"
X Link @DrChoueiri 2025-10-18T11:23Z 42.9K followers, 6661 engagements
"Landmark practice-changing readout delivered by #Charlesgayer shifting SOC. DESTINY-Breast05 Ph. III shows T-DXd beating T-DM1 post-neoadjuvant in high-risk HER2+ eBC (IDFS HR XXXX XX% CI 0.34-0.66 p 0.001). #ESMO25 #BreastCancer @myESMO @OncLive @OncoAlert @DanaFarber"
X Link @DrChoueiri 2025-10-18T15:19Z 42.9K followers, 2617 engagements
"Practice shifting huge win by #JunGuo in HER2-expressing la/mUC: DV+toripalimab chemo: PFS XXXX vs XXX mo (HR 0.36) and OS XXXX vs XXXX mo (HR 0.54). Grade3 TRAE XX% vs 87%. #ESMO25 #BladderCancer @myESMO @Annals_Oncology @OncoAlert"
X Link @DrChoueiri 2025-10-19T16:34Z 42.9K followers, 1554 engagements